Valvular & structural heart diseaseCohort study

Applying the TRILUMINATE Eligibility Criteria to Real-World Patients Receiving Tricuspid Valve Transcatheter Edge-to-Edge Repair

JACC Cardiovasc IntervPublished

  • Cohort study
  • multicentre (5 European centres)

Authors' conclusion

The observed differences in survival and HFH outcomes suggest a limited generalizability of TRILUMINATE to real-world conditions

Study context

Population
Real-world patients who underwent transcatheter tricuspid edge-to-edge repair (T-TEER) at 5 European centres, 2016–2022
Participants
962 patients
Exposure
TRILUMINATE-eligible vs TRILUMINATE-ineligible patients
Outcome
Symptomatic and survival outcome

Main finding

As reported in the abstract

Survival and HF hospitalisation · 1 year

Survival

HF hospitalisation

Observational data: associations, not effects.

Further findings

TR ≤2+ at discharge

TR reduction, NYHA class, quality of life, exercise capacity

Comparable in both groups

Baseline characteristics

Eligible had superior LV function and fewer comorbidities

Original publication

Applying the TRILUMINATE Eligibility Criteria to Real-World Patients Receiving Tricuspid Valve Transcatheter Edge-to-Edge Repair. JACC Cardiovasc Interv. Published 20 November 2023. doi:10.1016/j.jcin.2023.11.014

Summarised from the published abstract; every number is checked against it